Obesity Pillars最新文献

{"title":"Obesity and advocacy: A joint clinical perspective and expert review from the obesity medicine association and the obesity action coalition - 2024","authors":"","doi":"10.1016/j.obpill.2024.100119","DOIUrl":"10.1016/j.obpill.2024.100119","url":null,"abstract":"<div><h3>Background</h3><p>This joint clinical perspective by the Obesity Medicine Association (OMA) and Obesity Action Coalition (OAC) provides clinicians an overview of the role of advocacy in improving the lives of patients living with the disease of obesity, as well as describes opportunities how to engage in advocacy.</p></div><div><h3>Methods</h3><p>This joint clinical perspective is based upon scientific evidence, clinical experiences of the authors, and peer review by the OMA leadership. The Obesity Medicine Association is the largest organization of physicians, nurse practitioners, physician associates, and other clinical experts (i.e., over 5000 members at time of print) who are engaged in improving the lives of patients affected by the disease of obesity. The OAC is a national nonprofit organization of more than 80,000 members who are dedicated to serving the needs of individuals living with obesity.</p></div><div><h3>Results</h3><p>Advocacy involves educational and public policy initiatives that through relationships, networks, and targeted strategies and tactics (e.g., traditional media, social media, petitions, and direct communication with policy makers), promote public awareness and establish public policies that help mitigate bias, stigma, and discrimination, and generally improve the lives of patients living with the disease of obesity.</p></div><div><h3>Conclusions</h3><p>An objective of advocacy is to foster collective involvement and community engagement, leading to collaborations that help empower patients living with obesity and their clinicians to seek and achieve changes in policy, environment, and societal attitudes. Advocacy may also serve to enhance public awareness, promote prevention, advance clinical research, develop safe and effective evidenced-based therapeutic interventions, and facilitate patient access to comprehensive and compassionate treatment of the complex disease of obesity.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000214/pdfft?md5=9a83b5950b320b432dd4f869fd486889&pid=1-s2.0-S2667368124000214-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141845571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of weight and waist gain in US South Asians: Findings from the Mediators of Atherosclerosis in South Asians Living in America (MASALA) study","authors":"","doi":"10.1016/j.obpill.2024.100118","DOIUrl":"10.1016/j.obpill.2024.100118","url":null,"abstract":"<div><h3>Background</h3><p>Weight and waist gain are significant concerns in adulthood. Both weight and waist gain are particularly important among South Asians, known to have an increased risk of developing chronic cardiometabolic complications at any body mass index compared to other racial and ethnic groups. The aim of this study was to investigate factors predicting weight and waist gain in a longitudinal cohort of South Asians living in the US (United States).</p></div><div><h3>Methods</h3><p>This was a prospective analysis using data from exam 1 (2010–2013) and exam 2 (2015–2018) of the Mediators of Atherosclerosis in South Asians Living in America (MASALA) study, a prospective cohort study of South Asians (recruited from San Francisco and Chicago), with a mean 4.8 years of follow-up.</p></div><div><h3>Results</h3><p>Of 634 participants studied (42.7 % women, mean age 55 years, BMI 25.7 kg/m2, weight 70.4 kg at exam 1), 34.7 % had gained ≥5 % weight and 32.3 % gained ≥5 % waist at exam 2. In the adjusted models, older age, higher number of years of US residence, and having diabetes were associated with lower odds of weight gain; being female and having higher adiponectin were associated with higher odds of weight gain. Being female and being employed full/part time or being retired predicted lower likelihood of waist gain. Being single, separated/divorced, having a higher leptin and a higher C-reactive protein level predicted higher likelihood of waist gain.</p></div><div><h3>Conclusions</h3><p>The current study identified several social, demographic, and clinical factors that can serve as targets for obesity interventions among US South Asians. In addition, this study also raises hypotheses about associations of adipokine levels with weight and waist gain.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000202/pdfft?md5=a7f7371cf5672a3fbfadd79e77798418&pid=1-s2.0-S2667368124000202-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141960401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastrointestinal delivery of bitter hop extract reduces appetite and food cravings in healthy adult women undergoing acute fasting","authors":"Edward Walker ,&nbsp;Kim Lo ,&nbsp;Pramod Gopal","doi":"10.1016/j.obpill.2024.100117","DOIUrl":"https://doi.org/10.1016/j.obpill.2024.100117","url":null,"abstract":"<div><h3>Background</h3><p>Dietary restrictions or reductions such as fasting for weight loss are often difficult to adhere to due to increased appetite and food cravings. Recently, gastrointestinal delivery of bitter hops has been shown to be effective at reducing appetite in men. Our aim was to determine the effect of a bitter hop extract on appetite and cravings in women, using a 24 h, water-only fast.</p></div><div><h3>Methods</h3><p>This was a randomized, double-blind, cross-over treatment study. Thirty adult women were recruited and required to fast for 24 h from 1800 h to 1800 h on three occasions and given an <em>ad libitum</em> meal to break each fast. Treatments of either a placebo or one of two doses (high dose; HD: 250 mg or low dose; LD: 125 mg) of a bitter hop-based appetite suppressant (Amarasate®) were given twice per day at 16 and 20 h into the fast.</p></div><div><h3>Results</h3><p>The HD and LD treatment groups exhibited a significant (<em>p</em> &lt; 0.05) reduction in appetite and cravings for food when compared to the placebo control. Two participants reported loose stools and one reported heartburn while on the HD treatment, and one participant reported loose stools while on the LD treatment.</p></div><div><h3>Conclusion</h3><p>These data suggest that appetite suppressant co-therapy may be useful in reducing hunger during fasting in women and shows that gastrointestinal delivery of bitter compounds may also be an effective method of reducing cravings for food.</p><p>This trial received ethical approval from the Northen B New Zealand Human Disability and Ethics committee (Northern B Health and Disability Ethics Committee (2022 EXP 10995) and was prospectively registered with the Australian New Zealand Clinical Trial Registry (ACTRN12622000107729).</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000196/pdfft?md5=b69372a9d79b2d1f5be5c39ba35b2aa5&pid=1-s2.0-S2667368124000196-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141543786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuropathy of Diabetes Following Initiation of a Low-Carbohydrate Diet: Case Report","authors":"Mark Jamal Sahyouni,&nbsp;Luis Anthony Acevedo,&nbsp;Sofia Cristina Rodriguez,&nbsp;Justin Armond Chiles,&nbsp;Nicholas Joseph Pennings","doi":"10.1016/j.obpill.2024.100115","DOIUrl":"10.1016/j.obpill.2024.100115","url":null,"abstract":"<div><h3>Introduction</h3><p>This case study portrays an unusual case of treatment-induced neuropathy of diabetes (TIND) in a patient with uncontrolled type 2 diabetes (T2D) who achieved rapid improvement in glucose control primarily with dietary intervention. Initial presentation was 50-year-old white male with a long-standing history of obesity and a family history of T2D with a screening glucose level &gt;500mg/dL by glucometer, HbA1c of 14.9%, and initial weight 213lbs.</p></div><div><h3>Methods</h3><p>The initial intervention included a low-carbohydrate diet, metformin, and a continuous glucose monitor (CGM). Semaglutide was added after seven days.</p></div><div><h3>Results</h3><p>His glycemia was within the target range within three weeks. Four weeks after initiation of therapy, he developed TIND symptoms consisting of burning, tightness, and numbness of bilateral feet along with 10/10 pain. At three months, his HbA1c dropped to 6.9% and his weight to 195lbs. Treatment of his TIND reduced his pain from 10/10 to 2/10.</p></div><div><h3>Conclusion</h3><p>Whereas TIND is commonly associated with the use of insulin or sulfonylureas, this study adds evidence to the paucity of literature regarding TIND precipitated by dietary intervention.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000172/pdfft?md5=5264353f4fd41999bd887942c0829d18&pid=1-s2.0-S2667368124000172-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141402815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In-hospital outcomes in metabolically healthy and unhealthy individuals over 65 years of age with obesity undergoing percutaneous intervention for acute coronary syndrome: A nationwide propensity-matched analysis (2016–2020)","authors":"Rupak Desai ,&nbsp;Aobo Li ,&nbsp;Avilash Mondal ,&nbsp;Sashwat Srikanth ,&nbsp;Alka Farmer ,&nbsp;Lin Zheng","doi":"10.1016/j.obpill.2024.100114","DOIUrl":"https://doi.org/10.1016/j.obpill.2024.100114","url":null,"abstract":"<div><h3>Background</h3><p>The obesity paradox in patients with coronary artery disease is well established, but the role of the metabolic syndrome associated with obesity is not well studied. Our study aims to evaluate the in-hospital outcomes of percutaneous coronary intervention (PCI) in metabolically healthy individuals with obesity (MHO) and metabolically unhealthy (MUHO) individuals with obesity over 65 years of age with acute coronary syndrome (ACS) between 2016 and 2020.</p></div><div><h3>Methods</h3><p>This was a retrospective and observational study. Patients were identified through utilizing the National Inpatient Sample (NIS) Database (2016–2020) and ICD-10 codes. By employing a <em>t</em>-test and Pearson's Chi-square test, we assessed and contrasted the initial attributes, concurrent conditions, and results pertaining to all-cause mortality (ACM), cardiogenic shock (CS), length of stay (LOS), and hospitalization expense. Moreover, propensity score matching was conducted in a 1:1 ratio with respect to age, gender, and race. We also utilized multivariable logistic regression to compare MHO and MUHO in terms of the impact on all-cause mortality.</p></div><div><h3>Results</h3><p>Out of a total of 135,395 patients identified, 2995 patients with MUHO were matched with 2995 MHO patients. Patients in the MUHO group had a higher prevalence of chronic pulmonary disease (24.9 % vs. 19.5 %), peripheral vascular disease (9.3 % vs. 6.7 %), hypothyroidism (16 % vs. 11.5 %), prior myocardial infarction (15.9 % vs. 6.2 %), and prior stroke (7.5 % vs. 2.8 %). Patients in the MHO group had a higher ACM (12.4 % vs. 2.8 %, p &lt; 0.001), CS (18.55 % vs. 7 %, p &lt; 0.001), stroke (2.2 % vs. 1 %, p &lt; 0.001), ventricular assist device insertions (5.2 % vs. 2.7 %, p &lt; 0.001), and IABP insertions (8.8 % vs. 3.8 %) compared to the MUHO cohort.</p></div><div><h3>Conclusion</h3><p>Our study revealed an obesity paradox in individuals over 65 years of age undergoing PCI demonstrating worse outcomes, including higher in-hospital mortality, CS, stroke, Ventricular assist device and IABP insertion in MHO patients compared to the MUHO cohort.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000160/pdfft?md5=0226893a08510e717f417b4649aaba52&pid=1-s2.0-S2667368124000160-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141164049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Special considerations for the child with obesity: An Obesity Medicine Association (OMA) clinical practice statement (CPS) 2024","authors":"Suzanne Cuda,&nbsp;Marisa Censani,&nbsp;Valerie O'Hara,&nbsp;Jennifer Paisley,&nbsp;Roohi Kharofa,&nbsp;Rushika Conroy,&nbsp;Brooke Sweeney,&nbsp;Cristina Fernandez,&nbsp;Meredith L. Dreyer Gillette,&nbsp;Nancy T. Browne","doi":"10.1016/j.obpill.2024.100113","DOIUrl":"10.1016/j.obpill.2024.100113","url":null,"abstract":"<div><h3>Background</h3><p>This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) details assessment and management of the child with overweight or obesity. The term “child” is defined as the child between 2 and 12 years of age. Because children are in a continual state of development during this age range, we will specify when our discussion applies to subsets within this age range. For the purposes of this CPS, we will use the following definitions: overweight in the child is a body mass index (BMI) ≥ 85th and &lt;95th percentile, obesity in the child is a BMI ≥95th percentile, and severe obesity is a BMI ≥120% of the 95th percentile.</p></div><div><h3>Methods</h3><p>The information and clinical guidance in this <span>OMA</span> Clinical Practice Statement are based on scientific evidence, supported by medical literature, and derived from the clinical perspectives of the authors.</p></div><div><h3>Results</h3><p>This OMA Clinical Practice Statement provides an overview of prevalence of disease in this population, reviews precocious puberty in the child with obesity, discusses the current and evolving landscape of the use of anti-obesity medications in children in this age range, discusses the child with obesity and special health care needs, and reviews hypothalamic obesity in the child.</p></div><div><h3>Conclusions</h3><p>This OMA Clinical Practice Statement on the child with obesity is an evidence based review of the literature and an overview of current recommendations. This CPS is intended to provide a roadmap to the improvement of the health of children with obesity, especially those with metabolic, physiological, psychological complications and/or special healthcare needs. This CPS addresses treatment recommendations and is designed to help the clinician with clinical decision making.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000159/pdfft?md5=084fe606099e8a1bea3be311f1cde0e6&pid=1-s2.0-S2667368124000159-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141137374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of concomitant antiobesity medication use with endoscopic sleeve gastroplasty in clinical US settings","authors":"Khushboo Gala ,&nbsp;Wissam Ghusn ,&nbsp;Vitor Brunaldi ,&nbsp;Christopher McGowan ,&nbsp;Reem Z. Sharaiha ,&nbsp;Daniel Maselli ,&nbsp;Brandon Vanderwel ,&nbsp;Prashant Kedia ,&nbsp;Michael Ujiki ,&nbsp;Eric Wilson ,&nbsp;Eric J. Vargas ,&nbsp;Andrew C. Storm ,&nbsp;Barham K. Abu Dayyeh","doi":"10.1016/j.obpill.2024.100112","DOIUrl":"10.1016/j.obpill.2024.100112","url":null,"abstract":"<div><h3>Background</h3><p>To evaluate the weight loss outcomes of the large US cohort of patients undergoing endoscopic sleeve gastroplasty (ESG) with or without concomitant anti-obesity (AOM) use.</p></div><div><h3>Methods</h3><p>We performed a retrospective analysis of adult patients who underwent ESG from seven different sites, from January 1, 2020 to November 30, 2022. Percent total body weight loss (%TBWL) and %excess weight loss (%EWL) were calculated based on baseline weight at the procedure. Medication use was considered if the subject received a prescribed AOM during the study period. SPSS (version 29.0) was used for statistical analyses.</p></div><div><h3>Results</h3><p>A total of 1506 patients were included (1359 (90.2 %) no AOM use and 147 (9.8 %) AOM use). Patients who were on an active AOM at the time of the procedure had a significantly lower TBWL% as compared to patients not on AOMs at 6 months. At the 24-month visit, patients who were prescribed AOMs after the 12-month visit had a significantly higher TBWL% and EWL% as compared to patients who were on active AOM at the time of the procedure. There was no significant difference between classes of medications at any time point, however, patients on a GLP-1RA had a trend towards improved weight loss at 18 and 24 months.</p></div><div><h3>Conclusion</h3><p>In this large, real-world cohort of patients from the United States, data signal that with the use of pharmacotherapy at the appropriate time, patients can achieve optimal results.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000147/pdfft?md5=ae8e9cd8ce4d7e051f284d376bfc6c29&pid=1-s2.0-S2667368124000147-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141043930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stronger control of eating 3 months after sleeve gastrectomy predicts successful weight loss outcomes at one year","authors":"Ellina Lytvyak ,&nbsp;Amir Zarrinpar ,&nbsp;Cecilia Dalle Ore ,&nbsp;Euyhyun Lee ,&nbsp;Keila Yazdani-Boset ,&nbsp;Santiago Horgan ,&nbsp;Eduardo Grunvald","doi":"10.1016/j.obpill.2024.100111","DOIUrl":"https://doi.org/10.1016/j.obpill.2024.100111","url":null,"abstract":"<div><h3>Background</h3><p>Weight loss response to sleeve gastrectomy (SG) is variable and predicting the effectiveness of surgery is challenging and elusive. The aim of our study was to assess and quantify the association between eating control and weight loss outcomes and identify the control of eating (CoE) attributes during the early postoperative period that might predict good vs. poor response to SG at one year.</p></div><div><h3>Methods</h3><p>A prospective longitudinal cohort study using the Control of Eating Questionnaire (CoEQ) was designed as a series before and at 3-, 6-, and 12-months post-SG. Primary outcomes were changes in CoE attributes and percent of total weight loss (%TWL) 12-months post-surgery. Subjects were categorized based on %TWL as good (GR, ≥25 %) or poor responders (PR, &lt;25 %). A receiver operating characteristic and logistic regression analyses were performed.</p></div><div><h3>Results</h3><p>We included 41 participants (80.5% females, 51.2% Hispanic, mean age 41.7±10.6, median baseline body mass index (BMI) 43.6 kg/m² [range 35.2–66.3]) who completed the CoEQ at all four timepoints. The “Difficulty to control eating” score at 3 months revealed the highest area under the curve (AUC) (AUC 0.711; 95%CI 0.524–0.898; p=0.032). In a trade-off between a high Youden index and high sensitivity, the “Difficulty to control eating” score of 7 at 3 months was identified as the optimal cut-off for distinguishing between GRs and PRs. Score ≤7 at 3 months was strongly independently associated with a successful weight loss target of 25%TWL at one-year post-SG (Relative Risk 4.43; 95%CI 1.06–18.54; p=0.042).</p></div><div><h3>Conclusion</h3><p>“Difficulty to control eating” score at 3 months post-SG is an independent early predictor of optimal response (achieving a successful TWL target of ≥25 % at one-year post-SG). Our results support the utility of this easy-to-administer validated tool for predicting the effectiveness of SG and may assist in identifying individuals with suboptimal response early and helping them with interventions to attain optimal weight loss targets.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000135/pdfft?md5=683e2eabbbb146969ab1f77cd4840471&pid=1-s2.0-S2667368124000135-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140900997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differentiating monogenic and syndromic obesities from polygenic obesity: Assessment, diagnosis, and management","authors":"Angela K. Fitch ,&nbsp;Sonali Malhotra ,&nbsp;Rushika Conroy","doi":"10.1016/j.obpill.2024.100110","DOIUrl":"10.1016/j.obpill.2024.100110","url":null,"abstract":"<div><h3>Background</h3><p>Obesity is a multifactorial neurohormonal disease that results from dysfunction within energy regulation pathways and is associated with increased morbidity, mortality, and reduced quality of life. The most common form is polygenic obesity, which results from interactions between multiple gene variants and environmental factors. Highly penetrant monogenic and syndromic obesities result from rare genetic variants with minimal environmental influence and can be differentiated from polygenic obesity depending on key symptoms, including hyperphagia; early-onset, severe obesity; and suboptimal responses to nontargeted therapies. Timely diagnosis of monogenic or syndromic obesity is critical to inform management strategies and reduce disease burden. We outline the physiology of weight regulation, role of genetics in obesity, and differentiating characteristics between polygenic and rare genetic obesity to facilitate diagnosis and transition toward targeted therapies.</p></div><div><h3>Methods</h3><p>In this narrative review, we focused on case reports, case studies, and natural history studies of patients with monogenic and syndromic obesities and clinical trials examining the efficacy, safety, and quality of life impact of nontargeted and targeted therapies in these populations. We also provide comprehensive algorithms for diagnosis of patients with suspected rare genetic causes of obesity.</p></div><div><h3>Results</h3><p>Patients with monogenic and syndromic obesities commonly present with hyperphagia (ie, pathologic, insatiable hunger) and early-onset, severe obesity, and the presence of hallmark characteristics can inform genetic testing and diagnostic approach. Following diagnosis, specialized care teams can address complex symptoms, and hyperphagia is managed behaviorally. Various pharmacotherapies show promise in these patient populations, including setmelanotide and glucagon-like peptide-1 receptor agonists.</p></div><div><h3>Conclusion</h3><p>Understanding the pathophysiology and differentiating characteristics of monogenic and syndromic obesities can facilitate diagnosis and management and has led to development of targeted pharmacotherapies with demonstrated efficacy for reducing body weight and hunger in the affected populations.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000123/pdfft?md5=ef18eb01d9e247c0054d2b3730d24d2e&pid=1-s2.0-S2667368124000123-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140766442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Obesity pillars roundtable: Body mass index and body composition in black and female individuals. Race-relevant or racist? Sex-relevant or sexist?” [Obesity Pillars 4C (2022) 100044]","authors":"Harold Edward Bays ,&nbsp;Sylvia Gonsahn-Bollie ,&nbsp;Courtney Younglove ,&nbsp;Sean Wharton","doi":"10.1016/j.obpill.2024.100105","DOIUrl":"10.1016/j.obpill.2024.100105","url":null,"abstract":"","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266736812400007X/pdfft?md5=e2ec63f3922a3ed3a882c1af3a0d02b5&pid=1-s2.0-S266736812400007X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140281860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}